ES2237461T3 - Uso de retigabina para el tratamiento de dolores neuropaticos. - Google Patents

Uso de retigabina para el tratamiento de dolores neuropaticos.

Info

Publication number: ES2237461T3
Authority: ES; Spain
Prior art keywords: pain; treatment; prophylaxis; compound; formula
Prior art date: 1999-09-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES00969283T

Other languages

English (en)

Spanish (es)

Inventor

Chris Rundfeldt

Reni Bartsch

Angelika Rostock

Christine Tober

Rita Dost

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bausch Health US LLC

Original Assignee

Xcel Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-27

Filing date

2000-09-22

Publication date

2005-08-01

2000-09-22 Application filed by Xcel Pharmaceuticals Inc filed Critical Xcel Pharmaceuticals Inc

2005-08-01 Application granted granted Critical

2005-08-01 Publication of ES2237461T3 publication Critical patent/ES2237461T3/es

2020-09-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 26
208000002193 Pain Diseases 0.000 title claims description 69
230000036407 pain Effects 0.000 title claims description 63
PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 title description 19
229960003312 retigabine Drugs 0.000 title description 16
208000004454 Hyperalgesia Diseases 0.000 claims abstract description 34
208000004296 neuralgia Diseases 0.000 claims abstract description 23
206010053552 allodynia Diseases 0.000 claims abstract description 13
238000011321 prophylaxis Methods 0.000 claims abstract description 12
150000001875 compounds Chemical class 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 3
230000002981 neuropathic effect Effects 0.000 claims description 12
238000007906 compression Methods 0.000 claims description 9
230000006835 compression Effects 0.000 claims description 9
230000000917 hyperalgesic effect Effects 0.000 claims description 7
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 5
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 5
208000003728 Vulvodynia Diseases 0.000 claims description 3
206010069055 Vulvovaginal pain Diseases 0.000 claims description 3
208000035824 paresthesia Diseases 0.000 claims description 3
201000001119 neuropathy Diseases 0.000 claims description 2
230000007823 neuropathy Effects 0.000 claims description 2
208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
208000020339 Spinal injury Diseases 0.000 claims 1
239000002537 cosmetic Substances 0.000 claims 1
206010044652 trigeminal neuralgia Diseases 0.000 claims 1
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 25
208000035154 Hyperesthesia Diseases 0.000 description 23
238000006243 chemical reaction Methods 0.000 description 19
208000021722 neuropathic pain Diseases 0.000 description 19
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 13
230000000694 effects Effects 0.000 description 13
229960002870 gabapentin Drugs 0.000 description 12
210000005036 nerve Anatomy 0.000 description 11
230000008447 perception Effects 0.000 description 10
210000000278 spinal cord Anatomy 0.000 description 10
241000700159 Rattus Species 0.000 description 8
230000006378 damage Effects 0.000 description 8
229940079593 drug Drugs 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
238000002266 amputation Methods 0.000 description 7
230000000202 analgesic effect Effects 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
230000001773 anti-convulsant effect Effects 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
210000000929 nociceptor Anatomy 0.000 description 6
230000008058 pain sensation Effects 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
239000001961 anticonvulsive agent Substances 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002483 medication Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
208000004983 Phantom Limb Diseases 0.000 description 4
206010056238 Phantom pain Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
229960000623 carbamazepine Drugs 0.000 description 4
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
108091008700 nociceptors Proteins 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
229960004528 vincristine Drugs 0.000 description 4
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 3
108090000189 Neuropeptides Proteins 0.000 description 3
208000000114 Pain Threshold Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
229960003965 antiepileptics Drugs 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000003141 lower extremity Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000004126 nerve fiber Anatomy 0.000 description 3
230000037040 pain threshold Effects 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
238000002636 symptomatic treatment Methods 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
206010001497 Agitation Diseases 0.000 description 2
241001086826 Branta bernicla Species 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
108700002232 Immediate-Early Genes Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000005298 acute pain Diseases 0.000 description 2
229940125681 anticonvulsant agent Drugs 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
239000000835 fiber Substances 0.000 description 2
229960003667 flupirtine Drugs 0.000 description 2
230000004047 hyperresponsiveness Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
206010062198 microangiopathy Diseases 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000000626 neurodegenerative effect Effects 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
238000005457 optimization Methods 0.000 description 2
230000037324 pain perception Effects 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
239000013558 reference substance Substances 0.000 description 2
230000035807 sensation Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000033001 Complex partial seizures Diseases 0.000 description 1
206010013142 Disinhibition Diseases 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010029174 Nerve compression Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003070 anti-hyperalgesia Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
230000009956 central mechanism Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000000773 effect on pain Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000002650 habitual effect Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007803 itching Effects 0.000 description 1
230000001535 kindling effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
229960003938 moxonidine Drugs 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000001067 neuroprotector Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000008289 pathophysiological mechanism Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
210000001032 spinal nerve Anatomy 0.000 description 1
230000008925 spontaneous activity Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
229960004394 topiramate Drugs 0.000 description 1
229960004380 tramadol Drugs 0.000 description 1
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
229940102566 valproate Drugs 0.000 description 1
230000001790 virustatic effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000010374 vitamin B1 Nutrition 0.000 description 1
239000011691 vitamin B1 Substances 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
235000019158 vitamin B6 Nutrition 0.000 description 1
239000011726 vitamin B6 Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES00969283T 1999-09-27 2000-09-22 Uso de retigabina para el tratamiento de dolores neuropaticos. Expired - Lifetime ES2237461T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/406,135 US6117900A (en)	1999-09-27	1999-09-27	Use of retigabine for the treatment of neuropathic pain
US406135		1999-09-27

Publications (1)

Publication Number	Publication Date
ES2237461T3 true ES2237461T3 (es)	2005-08-01

Family

ID=23606675

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES00969283T Expired - Lifetime ES2237461T3 (es)	1999-09-27	2000-09-22	Uso de retigabina para el tratamiento de dolores neuropaticos.

Country Status (35)

Country	Link
US (1)	US6117900A (de)
EP (1)	EP1223927B1 (de)
JP (1)	JP2003510273A (de)
KR (1)	KR100730829B1 (de)
CN (2)	CN101444498A (de)
AR (1)	AR026163A1 (de)
AT (1)	ATE288748T1 (de)
AU (1)	AU777764B2 (de)
BG (1)	BG65795B1 (de)
BR (1)	BR0014293A (de)
CA (2)	CA2384504C (de)
CZ (1)	CZ295980B6 (de)
DE (1)	DE50009504D1 (de)
DK (1)	DK1223927T3 (de)
EE (1)	EE05073B1 (de)
ES (1)	ES2237461T3 (de)
HK (1)	HK1052471A1 (de)
HR (1)	HRP20020234A2 (de)
HU (1)	HUP0202853A3 (de)
IL (3)	IL148309A0 (de)
IS (1)	IS6303A (de)
MX (1)	MXPA02003179A (de)
NO (1)	NO329744B1 (de)
NZ (1)	NZ517616A (de)
PL (1)	PL200847B1 (de)
PT (1)	PT1223927E (de)
RS (1)	RS50091B (de)
RU (1)	RU2264813C2 (de)
SI (1)	SI1223927T1 (de)
SK (1)	SK286057B6 (de)
TR (1)	TR200200706T2 (de)
TW (1)	TWI257304B (de)
UA (1)	UA72550C2 (de)
WO (1)	WO2001022953A2 (de)
ZA (1)	ZA200202449B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6525062B2 (en)	2000-06-09	2003-02-25	The Regents Of The University Of California	Method of treating pain using nalbuphine and opioid antagonists
US6348486B1 (en)	2000-10-17	2002-02-19	American Home Products Corporation	Methods for modulating bladder function
US6589986B2 (en) *	2000-12-20	2003-07-08	Wyeth	Methods of treating anxiety disorders
WO2002061075A1 (fr) *	2001-02-01	2002-08-08	Takeda Chemical Industries, Ltd.	Proteine de recepteur couple aux proteines g et adn correspondant
IL157313A0 (en)	2001-02-20	2004-02-19	Bristol Myers Squibb Co	Modulators of kcnq potassium channels and uses thereof
AR033095A1 (es) *	2001-04-04	2003-12-03	Wyeth Corp	Metodos para el tratamiento de motilidad gastrica hiperactiva
JP2006503025A (ja) *	2002-09-05	2006-01-26	サイオスインク．	ｐ３８ＭＡＰキナーゼの抑制による疼痛治療
US20080039461A1 (en) *	2002-09-05	2008-02-14	Protter Andrew A	Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en)	2002-10-21	2009-12-15	Ramot At Tel Aviv University	Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003296954A1 (en) *	2002-12-13	2004-07-09	The Regents Of The University Of California	Analgesic combination comprising nalbuphine
PT1578740E (pt) *	2002-12-27	2007-05-31	Lundbeck & Co As H	Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
BR0317748A (pt) *	2002-12-27	2005-11-22	Lundbeck & Co As H	Composto, composição farmacêutica, e,uso de um composto
WO2004096767A1 (en) *	2003-04-25	2004-11-11	H. Lundbeck A/S	Sustituted indoline and indole derivatives
US7799832B2 (en) *	2003-10-23	2010-09-21	Valeant Pharmaceuticals North America	Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en)	2004-03-12	2012-02-11	Lundbeck & Co As H	Substituted morpholine and thiomorpholine derivati
WO2006092143A1 (en)	2005-03-03	2006-09-08	H. Lundbeck A/S	Substituted pyridine derivatives
US7960436B2 (en) *	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) *	2006-08-18	2008-02-21	Valeant Pharmaceuticals North America	Derivatives of 1,3-diamino benzene as potassium channel modulators
US8293911B2 (en) *	2006-08-23	2012-10-23	Valeant Pharmaceuticals International	Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) *	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) *	2006-10-10	2014-05-13	Valeant Pharmaceuticals International	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
WO2008066900A1 (en) *	2006-11-28	2008-06-05	Valeant Pharmaceuticals International	1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) *	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) *	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) *	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8765815B2 (en) *	2007-09-20	2014-07-01	Ramot At Tel-Aviv University Ltd.	N-phenyl anthranilic acid derivatives and uses thereof
US20100323016A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
CA2731008A1 (en) *	2008-07-18	2010-01-21	Valeant Pharmaceuticals International	Modified release formulation and methods of use
US20100323015A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
DE102009013611A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013613A1 (de)	2009-03-17	2010-09-23	Ratiopharm Gmbh	Trockenverarbeitung von Retigabin
IT1398282B1 (it) *	2009-07-30	2013-02-22	Difass S A Ora Farmapros S P A	Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) *	2009-10-06	2011-04-14	Johnson Controls Technology Company	Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) *	2010-03-31	2011-09-21	Mustafa Nevzat �La� Sanay�� A.�.	Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) *	2011-03-31	2012-04-10	Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России"	Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) *	2011-12-23	2013-07-24	山东创新药物研发有限公司	瑞替加滨的晶型d及其制备方法
US20130310385A1 (en)	2012-05-18	2013-11-21	Gruenenthal Gmbh	Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) *	2012-05-18	2016-05-24	Gruenenthal Gmbh	Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en)	2012-05-18	2016-04-26	Gruenenthal Gmbh	Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
CN103271899A (zh) *	2012-12-30	2013-09-04	北京阜康仁生物制药科技有限公司	瑞替加滨粉碎粒度在制剂中的应用
CN105919990A (zh) *	2016-06-29	2016-09-07	青岛云天生物技术有限公司	用于预防和治疗神经病理性疼痛的药物组合物及其用途
CN106176715A (zh) *	2016-06-29	2016-12-07	青岛云天生物技术有限公司	一种神经病理性疼痛治疗用药物组合物及其用途
WO2019014547A1 (en)	2017-07-14	2019-01-17	Texas Tech University System	FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
US11427531B2 (en)	2017-10-09	2022-08-30	Ramot At Tel-Aviv University Ltd.	Modulators of potassium ion and TRPV1 channels and uses thereof
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en)	2019-11-08	2021-05-14	Cynthia Louise HARDEN	Methods of treating depressive disorders
CN116847843A (zh)	2021-02-09	2023-10-03	泽农医药公司	用于治疗快感缺乏的电压门控的钾通道开放剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4200259A1 (de) *	1992-01-08	1993-07-15	Asta Medica Ag	Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) *	1995-10-26	1997-04-30	Asta Medica Ag	Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) *	1999-07-01	1999-09-01	Glaxo Group Ltd	Medical use

1999
- 1999-09-27 US US09/406,135 patent/US6117900A/en not_active Expired - Lifetime
2000
- 2000-09-21 TW TW089119495A patent/TWI257304B/zh not_active IP Right Cessation
- 2000-09-22 UA UA2002043557A patent/UA72550C2/uk unknown
- 2000-09-22 NZ NZ517616A patent/NZ517616A/xx not_active IP Right Cessation
- 2000-09-22 CZ CZ2002989A patent/CZ295980B6/cs not_active IP Right Cessation
- 2000-09-22 PL PL353393A patent/PL200847B1/pl not_active IP Right Cessation
- 2000-09-22 TR TR2002/00706T patent/TR200200706T2/xx unknown
- 2000-09-22 WO PCT/EP2000/009284 patent/WO2001022953A2/de not_active Ceased
- 2000-09-22 KR KR1020027003903A patent/KR100730829B1/ko not_active Expired - Fee Related
- 2000-09-22 CA CA002384504A patent/CA2384504C/en not_active Expired - Fee Related
- 2000-09-22 HR HR20020234A patent/HRP20020234A2/hr not_active Application Discontinuation
- 2000-09-22 CN CNA2008101752753A patent/CN101444498A/zh active Pending
- 2000-09-22 ES ES00969283T patent/ES2237461T3/es not_active Expired - Lifetime
- 2000-09-22 BR BR0014293-0A patent/BR0014293A/pt not_active Application Discontinuation
- 2000-09-22 AU AU79061/00A patent/AU777764B2/en not_active Ceased
- 2000-09-22 JP JP2001526165A patent/JP2003510273A/ja not_active Ceased
- 2000-09-22 DK DK00969283T patent/DK1223927T3/da active
- 2000-09-22 SI SI200030641T patent/SI1223927T1/xx unknown
- 2000-09-22 EE EEP200200145A patent/EE05073B1/xx not_active IP Right Cessation
- 2000-09-22 MX MXPA02003179A patent/MXPA02003179A/es active IP Right Grant
- 2000-09-22 CA CA002659048A patent/CA2659048A1/en not_active Abandoned
- 2000-09-22 AT AT00969283T patent/ATE288748T1/de active
- 2000-09-22 SK SK292-2002A patent/SK286057B6/sk not_active IP Right Cessation
- 2000-09-22 DE DE50009504T patent/DE50009504D1/de not_active Expired - Lifetime
- 2000-09-22 EP EP00969283A patent/EP1223927B1/de not_active Expired - Lifetime
- 2000-09-22 RU RU2002109240/15A patent/RU2264813C2/ru not_active IP Right Cessation
- 2000-09-22 RS YUP-203/02A patent/RS50091B/sr unknown
- 2000-09-22 IL IL14830900A patent/IL148309A0/xx active IP Right Grant
- 2000-09-22 HK HK03104879.5A patent/HK1052471A1/zh unknown
- 2000-09-22 CN CNB008133042A patent/CN100522155C/zh not_active Expired - Fee Related
- 2000-09-22 PT PT00969283T patent/PT1223927E/pt unknown
- 2000-09-22 HU HU0202853A patent/HUP0202853A3/hu unknown
- 2000-09-26 AR ARP000105028A patent/AR026163A1/es unknown
2002
- 2002-02-21 IL IL148309A patent/IL148309A/en not_active IP Right Cessation
- 2002-02-27 BG BG106450A patent/BG65795B1/bg unknown
- 2002-03-18 IS IS6303A patent/IS6303A/is unknown
- 2002-03-21 NO NO20021418A patent/NO329744B1/no not_active IP Right Cessation
- 2002-03-27 ZA ZA200202449A patent/ZA200202449B/xx unknown
2007
- 2007-10-30 IL IL187030A patent/IL187030A/en active IP Right Grant

Also Published As

Publication number	Publication date
BG65795B1 (bg)	2009-12-31
HRP20020234A2 (en)	2003-06-30
IL187030A (en)	2011-06-30
TWI257304B (en)	2006-07-01
KR100730829B1 (ko)	2007-06-20
CZ295980B6 (cs)	2005-12-14
RU2264813C2 (ru)	2005-11-27
AU7906100A (en)	2001-04-30
SK286057B6 (sk)	2008-02-05
IL148309A (en)	2007-12-03
AU777764B2 (en)	2004-10-28
HUP0202853A3 (en)	2003-10-28
EP1223927B1 (de)	2005-02-09
KR20020042691A (ko)	2002-06-05
RS50091B (sr)	2009-01-22
WO2001022953A3 (de)	2002-05-23
UA72550C2 (en)	2005-03-15
IL187030A0 (en)	2008-02-09
IS6303A (is)	2002-03-18
PT1223927E (pt)	2005-06-30
CA2384504C (en)	2009-05-26
RU2002109240A (ru)	2004-01-10
CZ2002989A3 (cs)	2002-08-14
NO329744B1 (no)	2010-12-13
SK2922002A3 (en)	2002-08-06
CA2384504A1 (en)	2001-04-05
HUP0202853A2 (hu)	2002-12-28
NZ517616A (en)	2002-12-20
MXPA02003179A (es)	2003-08-20
ATE288748T1 (de)	2005-02-15
PL200847B1 (pl)	2009-02-27
EE05073B1 (et)	2008-10-15
NO20021418L (no)	2002-03-21
IL148309A0 (en)	2002-09-12
NO20021418D0 (no)	2002-03-21
EP1223927A2 (de)	2002-07-24
HK1052471A1 (zh)	2003-09-19
ZA200202449B (en)	2003-03-26
CN1409632A (zh)	2003-04-09
JP2003510273A (ja)	2003-03-18
PL353393A1 (en)	2003-11-17
WO2001022953A2 (de)	2001-04-05
CN101444498A (zh)	2009-06-03
AR026163A1 (es)	2003-01-29
BG106450A (en)	2002-09-30
DE50009504D1 (de)	2005-03-17
BR0014293A (pt)	2002-05-21
CN100522155C (zh)	2009-08-05
TR200200706T2 (tr)	2002-10-21
US6117900A (en)	2000-09-12
EE200200145A (et)	2003-04-15
SI1223927T1 (de)	2005-08-31
DK1223927T3 (da)	2005-04-11
YU20302A (sh)	2005-03-15
CA2659048A1 (en)	2001-04-05

Publication	Publication Date	Title
ES2237461T3 (es)	2005-08-01	Uso de retigabina para el tratamiento de dolores neuropaticos.
ES2335067T3 (es)	2010-03-18	Uso de duloxetina en el tratamiento de la fibromialgia.
ES2291454T3 (es)	2008-03-01	Utilizacion de carbamatos para prevenir o tratar trastornos del movimiento.
ES2236551T3 (es)	2005-07-16	Combinacion de principios activos para el tratamiento medico de toxicomanias.
ES2342185T3 (es)	2010-07-02	Uso de (di)carbamatos de 2-fenil-1,2-etanodiol para el tratamiento de la epileptogenesis.
NZ546549A (en)	2007-11-30	Carbamate compounds for use in preventing or treating anxiety disorders
ES2983441T3 (es)	2024-10-23	Acetil-leucina para su uso en el tratamiento de síndrome de las piernas inquietas
PT626851E (pt)	2002-02-28	Utilizacao de 3,5-diamino-6-(2,3-diclorofenil)-1,2,4-triazina para a preparacao de um medicamento para o tratamento de certos tipos de dor e edema
AU2019457560B2 (en)	2025-04-10	Compositions and methods for inducing defecation
US9192602B2 (en)	2015-11-24	Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain
ES2270947T3 (es)	2007-04-16	Derivados de 2-indanilamino para la terapia de dolor cronico, agudo o inflamatorio.
CA3112166A1 (en)	2020-03-26	Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
WO2018220457A1 (en)	2018-12-06	Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache
ES2341517B1 (es)	2011-01-25	Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.
Hamid et al.	2005	Treatment of taeniasis and cysticercosis with praziquantel and albendazole
US9284281B2 (en)	2016-03-15	Indication of naphtho[2,3-F]quinoxaline-7,12-dione compound in alleviating pain
Nampiaparampil et al.	2008	Topiramate for the treatment of chronic corneal pain
WO2023148417A1 (es)	2023-08-10	Aceite de acebuchina para uso como hipotensor ocular
Chudasama et al.	2010	Study of process of intervention to control leptospirosis through chemoprophylaxis